Compare Summit Therapeutics Inc (SMMT) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Suncor Energy Inc. — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Suncor Energy Inc. trades at $69.02 (market cap $79.39B). The key difference: Suncor Energy Inc. is far larger — about 5.8× Summit Therapeutics Inc's market cap, and Suncor Energy Inc. pays a 2.55% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | SU | |
|---|---|---|
Market Cap | $13.79B | $79.39B |
Sector | Health | Energy |
52-Week High | $26.38 | $69.73 |
52-Week Low | $12.43 | $38.17 |
Enterprise Value | $13.11B | $86.13B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Suncor Energy (SU) trades at $67.89, up 0.83% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.54 and net income margin of 14.7%, supported by Q2 2026 earnings beating estimates. Recent news highlights leadership transition to Peter Zebedee as CEO in 2027 and a dividend declaration of $0.60 per share payable September 25, 2026.
Outlook remains positive due to robust cash flow and buyback increases, but risks include commodity price volatility and operational challenges from weather events. Analyst consensus is strongly bullish with 74% buy ratings, indicating confidence in sustained performance amid energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
